Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX)...
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) resulting from...
Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically...
Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology’s most serious and underserved supportive-care markets ...
Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)...
Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex...
Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March ...
New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy Jericho, New York, March 12, 2026 (GLOBE NEWSWIRE) -- Curanex...
New Advisors Bring 50+ Years of Leadership Experience With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc....
Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex”...